Cefotaxime/sulbactam: clinical and pharmacological characteristics | CMAC

Cefotaxime/sulbactam: clinical and pharmacological characteristics

Clinical Microbiology and Antimicrobial Chemotherapy. 2019; 21(3):212-216

​ Ortenberg E.A., Golub A.V.
10.36488/cmac.2019.3.212-216
third-generation cephalosporins sulbactam cefotaxime/ sulbactam antimicrobial resistance lower respiratory tract infections urinary tract infections
Section
Antimicrobials
Type
Review
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2019; 21(3):212-216

Abstract

The recently approved cefotaxime/sulbactam, combination of third-generation cephalosporin (cefotaxime) and beta-lactamase inhibitor (sulbactam), can combat resistance mechanisms associated with the production of serine beta-lactamases, including some extended spectrum beta-lactamases. This paper reviews the use of this combination antibiotic in clinical practice based on the current data on antimicrobial resistance in pathogens causing lower respiratory tract infections and the results of completed clinical studies of its efficacy and safety.

Eduard A. Ortenberg

Tyumen State Medical University, Tyumen, Russia

Alexey V. Golub

Smolensk State Medical University, Smolensk, Russia

  • 1. Tackling drug-resistant infections globally: final report and recommendations. Available at: https://amr-review.org/sites/default/files/160525_Final%20paper_with%20cover.pdf.
  • 2. Bush K. Past and present perspectives on β-lactamases. Antimicrob Agents Chemoter. 2018;62(10):e01076-18. DOI: 10.1128/AAC.01076-18
  • 3. Colodner R., Raz R. Extended-spectrum beta-lactamases: the end of cephalosporins? Isr Med Assoc J. 2005;7(5):336-338.
  • 4. Castanheira M., Doyle T.B., Mendes R.E., Sader H.S. Comparative activities of ceftazidime-avibactam and ceftolozane-tazobactam against Enterobacteriaceae isolates producing extended-spectrum β-lactamases from U.S. hospitals. Antimicrob Agents Chemother. 2019;63(7):e00160-19. DOI: 10.1128/AAC.00160-19
  • 5. Akova M. Sulbactam-containing β-lactamase inhibitor combinations. Clin Microbiol Infect. 2008;14(Suppl. 1):185-188. DOI: 10.1111/j.1469-0691.2007.01847.x
  • 6. Bauernfeind A. Perspectives of beta-lactamases inhibitors in therapy of infections caused by Escherichia coli and Klebsiella with plasmidic resistance to third generation cephalosporins. Infection. 1990;18(1):48-52. DOI: 10.1007/bf01644185
  • 7. Kozlov R.S., Martinovich A.A., Dekhnich A.V. Comparison of the in vitro efficacy of ceftriaxone and ceftriaxone/sulbactam against ESBL-producing Enterobacteriaceae strains. Vnutrennjaja medicina. 2008;5-6:84-86. Russian.
  • 8. Li C.-Q., Chen W., Wang T. Rationality of combination and proportion of cefotaxime/sulbactam in vitro. Chinese Journal of New Drugs. 2010;19(9):759-761.
  • 9. Yang W.-J., Shao Z.-J., Zeng Y., Luo G., Zhou -M. In vitro and in vivo synergistic antibacterial activity of cefotaxime/sulbactam. Chinese Journal of Antibiotics. 2008;33(8):487-490.
  • 10. Payasi A., Chaundhary M., Gupta A., Dwivedi V.K., Bhatnagar A. Pharmacokinetic study of sulbactomax. J Toxicol Sci. 2010;35(4):459-464. DOI: 10.2131/jts.35.459
  • 11. Kamath S.G., Varun H.V., Rani D.U., Aithal S., Patil U.N. Prescribing patterns of antimicrobials in surgical departments in a tertiary care hospital in south India. Int J Pharm Sci Res. 2014;5(3):1051-1058. DOI: 10.13040/IJPSR.0975-8232.5(3).1051-58
  • 12. Pareek A., Kulkarni M., Daga S., Deshpande A, Chandurkar N. Comparative evaluation of efficacy and safety of cefotaximesulbactam with amoxicillin-clavulanic acid in children with lower respiratory tract infections. Expert Opin Pharmacother. 2008;9(16):2751-2757. DOI: 10.1517/14656566.9.16.2751
  • 13. Report of the results of a clinical trial of a medicinal product for medical use according to the protocol “An open randomized comparative study to investigate the efficacy and safety of Klaruktam, a powder for the preparation of a solution for intravenous and intramuscular administration of 1000 mg + 500 mg (LLC Ruzfarma, Russia) and Claforan®, powder for preparation of a solution for intravenous and intramuscular administration of 1 g (Aventis Pharma Limited, produced by Pateon UK Limited, UK) in a hospitalized patients with community-acquired pneumonia.“ Moscow, St. Petersburg, Yaroslavl, 2016. Russian.
  • 14. Kaur K., Gupta A., Sharma A., Walia G., Singh B., Kaur K. Evaluation of efficacy and tolerability of cefotaxime and sulbactam versus cefepime and tazobactam in patients of urinary tract infection – a prospective comparative study. J Clin Diagn Res. 2014;8(11):HC05-8. DOI: 10.7860/JCDR/2014/9742.5090
  • 15. Makwana S.P., Solanki M.N., Dikshit R.K. Cefoperazone + sulbactam versus cefotaxime + sulbactam combination therapy for the treatment of complicated urinary tract infections in hospitalized patients: safety and efficacy analysis. Natl J Physiol Pharm Pharmacol. 2019;9(2):187-195. DOI: 10.5455/njppp.2019.9.1236526122018
  • 16. Kuzmenkov A.Yu, Trushin I.V, Avramenko A.A., Edelstein M.V., Dekhnich A.V., Kozlov R.S. AMRmap: an online platform for monitoring antibiotic resistance. Klinicheskaja mikrobiologija i antimikrobnaja himioterapija. 2017;19(2):84-90. Russian.
  • 17. Community-acquired pneumonia. Clinical recommendations. Russian Respiratory Society. Interregional Association of Clinical Microbiology and Antimicrobial Chemotherapy. 2018. Available at: http://spulmo.ru/obrazovatelnye-resursy/federalnyeklinicheskierekomendatsii/. Russian.
  • 18. Chronic obstructive pulmonary disease. Clinical recommendations. Russian Respiratory Society. Available at: http://spulmo.ru/upload/federal_klinicheskie_rekomendaciy_hobl.pdf. Russian.
Views
0 Abstract
0 PDF
0 Crossref citations
Shared